Compare Gilead Sciences, Inc. (GILD) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Newegg Commerce Inc — how do they compare? Gilead Sciences, Inc. trades at $135.62 (market cap $168.35B), while Newegg Commerce Inc trades at $19.08 (market cap $398.29M). The key difference: Gilead Sciences, Inc. is far larger — about 422.7× Newegg Commerce Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals.
| GILD | NEGG | |
|---|---|---|
Market Cap | $168.35B | $398.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $128.09 |
52-Week Low | $110.56 | $12.87 |
Enterprise Value | $191.42B | $397.09M |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
NEGG trades at $18.99, up 3.32% today, with a bullish technical signal from moving averages. Recent earnings beat expectations, showing improved profitability with a net income margin of 0.39% in 2025, up from negative margins in prior years. The company maintains a low P/S ratio of 0.28, but a high P/E of 73.16 reflects growth expectations. News highlights include AI shopping features and product launches, indicating innovation efforts.
Outlook: NEGG shows operational improvement with narrowing losses, but negative operating cash flow and high valuation multiples pose risks. The sole analyst coverage is bullish, yet investor caution is warranted due to competitive pressures and reliance on tech spending cycles. Upside depends on sustained revenue growth and margin expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
